You are here

Eisai to Present Latest Research about Alzheimer's Disease/Dementia Pipeline at The 14th International Conference on Alzheimer's & Parkinson's Diseases

WOODCLIFF LAKE, N.J., March 22, 2019 /PRNewswire/ -- Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., announces today that seven poster presentations from its Alzheimer's disease/dementia pipeline will be highlighted at the 14th International Conference on Alzheimer's & Parkinson's Diseases (AD/PD) on March 26-31 in Lisbon, Portugal.

Five of the presentations are from the two investigational compounds that are being jointly developed by Eisai and Biogen:  BAN2401, an anti-amyloid beta (Aβ) protofibril antibody for which a Phase 3 trial is being initiated and elenbecestat, an oral selective BACE1 inhibitor that is currently being studied in two ongoing Phase 3 studies (MISSION AD1/2).

One poster presentation will highlight the study design for the Open Label Extension portion of the BAN2401 Phase 2 study in early Alzheimer's disease (AD). Another poster presentation of E2027, a phosphodiesterase-9 (PDE9) inhibitor discovered and developed solely by Eisai, will feature pooled electrocardiogram (ECG) data, food effects and drug-drug interactions which helped guide dose selection for a Phase 2 study for dementia with Lewy bodies.

"Our data at this year's AD/PD conference highlights the steady progress we are making with our pipeline as well as our strong commitment to Alzheimer's disease and dementia," said Ivan Cheung, Chairman & CEO, Eisai Inc. "We are relentless in our pursuit of scientific innovation to help address the devastation so many patients and families experience living with these debilitating diseases."

AD/PD 2019 Presentations:

Product/Poster/Session
Number

Abstract title and scheduled presentation date

Poster Presentations


BAN2401

Abstract ID: ADPD9-2335

Poster No.: 177

 

Population Pharmacokinetic and Exposure-Response Analyses
for Efficacy and Safety of BAN2401 in Patients with Early
Alzheimer's Disease

March 27-28, 2019 (Wednesday)

BAN2401

Abstract ID: ADPD9-2329

Poster No.: 178

Long-Term Safety and Tolerability of BAN2401 in Early
Alzheimer's Disease: An Open Label Extension Study Design
for BAN2401-G000-201

March 27-28, 2019 (Wednesday)

Elenbecestat

Abstract ID: ADPD-2340

Poster No.: 234

Performance on the International Shopping List Test and
Subsequent Amyloid PET Positivity Rates in the Elenbecestat
MissionAD Program

March 27-28, 2019 (Wednesday)

Elenbecestat

Abstract ID: ADPD-2318

Poster No.: 238

 

Predicting Abnormal Memory From Assessment of Cognition
Using the CBB in the Elenbecestat MissionAD Global Phase 3
Program

March 27-28, 2019 (Wednesday)

Elenbecestat

Abstract ID: ADPD-2237

Poster No.: 425

 

Evaluation of Tau Deposition in Amyloid Positive MCI or Mild-
AD Dementia Subjects from the Elenbecestat MissionAD
Program Using [18F]PI-2620 PET

March 27-28, 2019 (Wednesday)

E2027

Abstract ID: ADPD9-1615

Poster No.: 670

Concentration Response Modeling of ECG Data for E2027 to
Inform Dose Selection for Phase 2 Dementia in Lewy Body
Study

March 27-28, 2019 (Wednesday)

General AD

Abstract ID: ADPD-0345

Poster No.: 333

Tau Proteoforms in Alzheimer's Disease and Progressive
Supranuclear Palsy Brains

March 29, 2019 (Friday)

This release discusses investigational uses of agents in development and is not intended to convey conclusions about efficacy or safety. There is no guarantee that such investigational agents will successfully complete clinical development or gain health authority approval.

[Notes to editors]

  1. Eisai obtained the global rights to study, develop, manufacture and market BAN2401 for the treatment of Alzheimer's disease pursuant to an agreement concluded with BioArctic in December 2007.
  2. About the Joint Development Agreement between Eisai and Biogen for Alzheimer's disease: Eisai and Biogen are collaborating on the joint development and commercialization of Alzheimer's disease treatments. Eisai serves as the lead in the co-development of elenbecestat, a BACE inhibitor, and BAN2401, an anti-Aβ protofibril antibody and the companies plan to pursue marketing authorizations for the two compounds worldwide. If approved, the companies will also co-promote the products in major markets, such as the United States, the European Union and Japan.

About Eisai Inc.

At Eisai Inc., human health care (hhc) is our goal. We give our first thoughts to patients and their families, and helping to increase the benefits health care provides. As the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., we have a passionate commitment to patient care that is the driving force behind our efforts to discover and develop innovative therapies to help address unmet medical needs.

Eisai is a fully integrated pharmaceutical business that operates in two global business groups: oncology and neurology (dementia-related diseases and neurodegenerative diseases). Each group functions as an end-to-end global business with discovery, development, and marketing capabilities. Our U.S. headquarters, commercial and clinical development organizations are located in New Jersey; our discovery labs are in Massachusetts and Pennsylvania; and our global demand chain organization resides in Maryland and North Carolina. To learn more about Eisai Inc., please visit us at www.eisai.com/US.

Contacts:

Libby Holman
201-746-2040
libby_holman@eisai.com

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/eisai-to-present-latest-research-about-alzheimers-diseasedementia-pipeline-at-the-14th-international-conference-on-alzheimers--parkinsons-diseases-300816842.html

SOURCE Eisai Inc.